

Successful time-course studies in animals

Highlights

- Building on the **success of our delivery technology in both animal models and human cells**, PYC are conducting 4 week time-course testing to **prove that drugs incorporating our Cell Penetrating Peptides (CPPs) have a sustained duration of action**
- A drug molecule utilising **PYC's delivery technology achieves a sustained effect over a 4-week time period in the eye of a mouse after a single low dose** (this is the maximum time period allowed under our current animal ethics protocol)
- Effectiveness of a drug over a sustained period as demonstrated in this model for PYC's technology allows for infrequent dosing **meaning greater patient compliance and better treatment outcomes (ie. Better drugs)**
- **PYC's CPP continues to outperform all competitive delivery technologies evaluated**

25 September 2019: Phylogica Limited trading as PYC Therapeutics (ASX: PYC) 'The Company' or 'PYC' has successfully completed a time-course evaluation of the effectiveness of a drug incorporating our Cell Penetrating Peptide (CPP) delivery technology in mice over a 4 week time period. The result demonstrates that the drug (an Anti-Sense Oligonucleotide or 'ASO') continues to achieve its desired effect throughout the full time period of the study (the maximum allowed under our current animal ethics protocol).

The result provides a positive indication for achieving an acceptable dosing regimen in humans when using PYC's technology to treat blinding eye diseases because it suggests that effective treatment can be achieved with significant time intervals between drug administration (ie. months between drug dosing). Longer time periods between drug dosing intervals generally increases patient compliance levels and leads to better treatment outcomes.

The result is particularly encouraging because of the low dose of drug that was administered in achieving this outcome (a single dose of 1.6 micrograms per eye which is ~60 times lower than the dose used in similar pre-clinical studies of 'naked' Anti-Sense Oligonucleotides)¹. This outcome builds on previous time-course results at earlier read-out intervals (see ASX announcement of 22 August 2019).

We are making significant progress towards the clinical development of our technology and this result further supports our prospects of successful human translation.

¹ Splice-Modulating Oligonucleotide QR-110 Restores CEP290 mRNA and Function in Human c.2991+1655A>G LCA10 Models. Michael E. Cheetham. Nucleic Acids (Molecular Therapy). Volume 12, 7 September 2018, Pages 730-740

ENDS

For further information, please contact:

INVESTORS

Rohan Hockings
CEO

Rohan.hockings@pyctx.com

About PYC Therapeutics

Phylogica Limited trading as PYC Therapeutics (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome ‘the delivery challenge’ and provide access for a wide range of potent and precise drug ‘cargoes’ to the ‘undruggable genome’ – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Tel: +61 8 6151 0994

pyctx.com

Phylogica Limited trading as PYC Therapeutics

ACN 098 391 961